Proteon CEO: New trial could be a path to market
After Proteon Therapeutics Inc.'s chronic kidney disease treatment failed a late clinical trial, the company is forging forward with a new plan that could take the drug to market.
The Waltham, Mass.-based company's treatment, vonapanitase, was originally developed by Kansas City entrepreneur Nick Franano. It's intended to help maintain blood flow through an arteriovenous fistula (AVF), a connection between an artery and a vein, used for patients on dialysis.
"What we're tr ying to do is not just…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Elise Reuter Source Type: news
More News: Chronic Kidney Disease | Clinical Trials | Dialysis | Health Management | Pharmaceuticals | Urology & Nephrology